February 26, 2015, by NCI Staff Researchers have identified genetic variations in children with brain cancer that are associated with hearing damage caused by the chemotherapy drug cisplatin. Children with these inherited variations who were treated with cisplatin had an increased risk of rapid hearing loss, the researchers reported in Nature Genetics. Cisplatin is an
Tamiflu is the current standard treatment for patients with influenza. A recent study has presented results demonstrating that treatment with Tamiflu reduces the time to relief of flu symptoms, however, increases the occurrence of nausea and vomiting. Tamiflu (Oseltamivir) is a neuraminidase inhibitor that blocks the activity of influenza virus enzymes. During the 2009 influenza
February 20, 2015, by NCI Staff In an effort to inform the cancer research community and public about new NCI resources, this blog will regularly feature tools, videos, and other materials recently posted on NCI websites, including www.cancer.gov. Some recent additions include a new catalog of widely used data sets from NCI-supported studies and programs,
February 18, 2015, by NCI Staff Mark Gilbert, M.D.ChiefNIH Neuro-Oncology Branch In November 2014, Mark Gilbert, M.D., became chief of the NIH Neuro-Oncology Branch. The Branch is a partnership between NCI and the National Institute of Neurological Disorders and Stroke. In this interview, Dr. Gilbert talks about the Branch’s priorities and new developments in neuro-oncology.
February 13, 2015, by NCI Staff Secondhand smoke exposure in the United States fell by 50 percent from 1999 to 2012, according to a new study by investigators at the Centers for Disease Control and Prevention (CDC). However, they estimated that 58 million people in the United States were still exposed to secondhand smoke through
February 11, 2015, by NCI Staff The Food and Drug Administration (FDA) has granted accelerated approval to palbociclib (Ibrance) for the initial treatment of breast cancer in postmenopausal women with metastatic disease. The approval is for the use of palbociclib in combination with the aromatase inhibitor letrozole. Palbociclib is the first FDA-approved cancer drug that works
February 6, 2015, by NCI Staff Patient undergoing CT of the abdomen. Drawing shows the patient on a table that slides through the CT machine, which takes x-ray pictures of the inside of the body. For the first time, Medicare will cover the costs of lung cancer screening for some beneficiaries, the Centers for Medicare
February 3, 2015, by NCI Staff Researchers have surveyed the genetic changes in nearly 300 head and neck cancers, revealing some previously unknown alterations that may play a role in the disease, including in patients whose cancer is associated with the human papillomavirus (HPV). HPV is the most common sexually transmitted virus in the United